Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Yellow Fever Human Infection Model With YF-17D

ID
Name
NL70951.058.19
Description
No antiviral treatment exists for yellow fever, only supportive care, and therefore we rely on prevention through vaccination. Although this vaccine is very effective, stockpiles are insufficient in outbreak situations and some people have a contraindication to be vaccinated. For those who are unprotected and at risk of yellow fever infection, treatment could be life saving.
Trial arms
Trial start
2023-02-17
Estimated PCD
2023-07-01
Trial end
2024-03-01
Status
Recruiting
Treatment
Yellow Fever Vaccine
vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
Arms:
intervention arm
Other names:
Stamaril (yellow fever vaccine)
Size
30
Primary endpoint
yellow fever 17D in urine
within 30 days of the vaccination
Eligibility criteria
Inclusion Criteria: * age 18-50 years Exclusion Criteria: * contraindication to receive YF-17D (immune deficiency, thymus illness) * previous YF vaccination * pregnancy * chicken egg allergy * hypersensitivity to any other substance in the YF-17D vaccine * interval of \< 4 weeks of another live attenuated vaccine
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'human infection model of yellow fever with the yellow fever 17D vaccine and viruria (virus in urine) as readout', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}
Updated at
2023-06-13

1 organization

1 product

1 indication

Organization
Leiden University Medical Center
Product
Yellow Fever Vaccine
Indication
Yellow fever